Zaditen shortage — ES supply status & alternatives

Zaditen

—

🇦🇺 AUST R 299192 · Care Pharmaceuticals Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇪🇸 ES🇮🇪 IE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Marketing-authorisation holders
Active ingredient (INN)	Zaditen
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No

Registrations on file	8

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇫🇷 FR

€4.33

Retail price

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders8 registrations · 5 MA holders

Product	Strength	Form	Market	MA holder	Status
Zaditen ketotifen	250 microgram	—	🇦🇺 AU	Care Pharmaceuticals Pty Ltd	Active
ZADITEN 0.25MG/ML EYE DROPS, SOLUTION	0.25MG	solution	🇬🇧 GB	LABORATOIRES THEA	Active
ZADITEN TABLETS 1MG	1MG	tablet	🇬🇧 GB	ALFASIGMA SPA	Active
Zaditen Elixir	1.38MG	zaditen	🇬🇧 GB	ALFASIGMA SPA	Active
ZADITEN ketotifen 250microgram/mL eye drops bottle	250microgram	—	🇦🇺 AU	Care Pharmaceuticals Pty Ltd	Active
ZADITEN ketotifen 250microgram/mL eye drops	250microgram	—	🇦🇺 AU	Care Pharmaceuticals Pty Ltd	Active
ZADITEN	—	tablet	🇨🇦 CA	TEVA CANADA LIMITED	Active
Zaditen - Dps	1MG	drops	🇨🇦 CA	NOVARTIS PHARMACEUTICALS CANADA INC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.